Prevention and therapy of osteoporosis: the roles of plain vitamin D and alfacalcidol
- PMID: 15232715
- DOI: 10.1007/s00296-004-0454-0
Prevention and therapy of osteoporosis: the roles of plain vitamin D and alfacalcidol
Abstract
Severe vitamin D deficiency was identified only in the first decades of the last century as the most common aetiology of rickets in children and osteomalacia in adults. It was later shown that vitamin D is not, as had been supposed, the biologically active principle for healing bone disease but must be hydroxylated in the liver and then finally in the kidney to become 1alpha,25-dihydroxy-cholecalciferol, a biologically highly active renal hormone. This study reviews the various principles, mechanisms, and approaches to the treatment of different forms of osteoporosis using vitamin D, alfacalcidol, and calcitriol therapy regimens.
Comment in
-
Questions on the superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis.Rheumatol Int. 2004 Nov;24(6):370. doi: 10.1007/s00296-004-0523-4. Epub 2004 Oct 13. Rheumatol Int. 2004. PMID: 15490174 No abstract available.
Similar articles
-
Improving the outcome of established therapies for osteoporosis by adding the active D-hormone analog alfacalcidol.Rheumatol Int. 2007 Dec;28(2):103-11. doi: 10.1007/s00296-007-0422-6. Epub 2007 Aug 1. Rheumatol Int. 2007. PMID: 17668216 Review.
-
Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis.Rheumatol Int. 2004 Mar;24(2):63-70. doi: 10.1007/s00296-003-0361-9. Epub 2003 Sep 25. Rheumatol Int. 2004. PMID: 14513268 Clinical Trial.
-
Vitamin D therapy of osteoporosis: plain vitamin D therapy versus active vitamin D analog (D-hormone) therapy.Calcif Tissue Int. 1999 Oct;65(4):295-306. doi: 10.1007/s002239900702. Calcif Tissue Int. 1999. PMID: 10485982 Review.
-
Rationale for active vitamin D and analogs in the treatment of osteoporosis.J Cell Biochem. 2003 Feb 1;88(2):381-6. doi: 10.1002/jcb.10328. J Cell Biochem. 2003. PMID: 12520540 Review.
-
Alfacalcidol versus plain vitamin D in the treatment of glucocorticoid/inflammation-induced osteoporosis.J Rheumatol Suppl. 2005 Sep;76:33-40. J Rheumatol Suppl. 2005. PMID: 16142849
Cited by
-
Alfacalcidol in men with osteoporosis: a prospective, observational, 2-year trial on 214 patients.Rheumatol Int. 2013 Mar;33(3):637-43. doi: 10.1007/s00296-012-2429-x. Epub 2012 Apr 8. Rheumatol Int. 2013. PMID: 22527138 Clinical Trial.
-
Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial).Rheumatol Int. 2007 Mar;27(5):425-34. doi: 10.1007/s00296-006-0288-z. Rheumatol Int. 2007. PMID: 17216477 Clinical Trial.
-
In elderly men and women treated for osteoporosis a low creatinine clearance of <65 ml/min is a risk factor for falls and fractures.Osteoporos Int. 2005 Dec;16(12):1683-90. doi: 10.1007/s00198-005-1903-7. Epub 2005 Jun 3. Osteoporos Int. 2005. PMID: 15933802
-
Questions on the superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis.Rheumatol Int. 2004 Nov;24(6):370. doi: 10.1007/s00296-004-0523-4. Epub 2004 Oct 13. Rheumatol Int. 2004. PMID: 15490174 No abstract available.
-
Improving the outcome of established therapies for osteoporosis by adding the active D-hormone analog alfacalcidol.Rheumatol Int. 2007 Dec;28(2):103-11. doi: 10.1007/s00296-007-0422-6. Epub 2007 Aug 1. Rheumatol Int. 2007. PMID: 17668216 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical